Diabetic neuropathy and oxidative stress: therapeutic perspectives.
Diabetic neuropathy and oxidative stress: therapeutic perspectives.
复制标题
DOI：
10.1155/2013/168039
复制
发表时间：
2013
影响因子：
--
通讯作者：
Abdollahi M
中科院分区：
文献类型：
--
作者：
Hosseini A;Abdollahi M
糖尿病神经病（DN）是一种广泛存在的致残性疾病，包括周围神经损伤。 DN 是在高血糖和代谢失衡（主要是氧化应激）的背景下发生的。大多数相关途径，如多元醇、晚期糖基化终产物、聚 ADP 核糖聚合酶、己糖胺和蛋白激酶 c 都起源于初始氧化应激。迄今为止，还没有确定 DN 的绝对治愈方法。虽然一些药物是常规使用的，但如果考虑到与氧化应激的所有病理生理学联系，则可以发现更多药物。在本文中，虽然对当前 DN 的治疗方法进行了回顾，但我们主要关注 DN 与氧化应激之间的联系以及即将出现的治疗方法，例如蛋白激酶 C、醛糖还原酶和晚期糖基化抑制剂。针对氧化应激及相关途径，正在研究的新药有：牛磺酸、乙酰左旋肉碱、α硫辛酸、蛋白激酶C抑制剂（ruboxistaurin）、醛糖还原酶抑制剂（非达司他、依帕司他、雷尼司他）、晚期糖基化终末产物抑制剂（苯磷硫胺、阿司匹林、氨基胍）、己糖胺途径抑制剂（苯磷硫胺）、多糖抑制剂等。 ADP-核糖聚合酶（烟酰胺）和血管紧张素转换酶抑制剂（群多普利）。开发治疗 DN 的现代药物是一个真正的挑战，需要大量的长期比较试验。
Diabetic neuropathy (DN) is a widespread disabling disorder comprising peripheral nerves' damage. DN develops on a background of hyperglycemia and an entangled metabolic imbalance, mainly oxidative stress. The majority of related pathways like polyol, advanced glycation end products, poly-ADP-ribose polymerase, hexosamine, and protein kinase c all originated from initial oxidative stress. To date, no absolute cure for DN has been defined; although some drugs are conventionally used, much more can be found if all pathophysiological links with oxidative stress would be taken into account. In this paper, although current therapies for DN have been reviewed, we have mainly focused on the links between DN and oxidative stress and therapies on the horizon, such as inhibitors of protein kinase C, aldose reductase, and advanced glycation. With reference to oxidative stress and the related pathways, the following new drugs are under study such as taurine, acetyl-L-carnitine, alpha lipoic acid, protein kinase C inhibitor (ruboxistaurin), aldose reductase inhibitors (fidarestat, epalrestat, ranirestat), advanced glycation end product inhibitors (benfotiamine, aspirin, aminoguanidine), the hexosamine pathway inhibitor (benfotiamine), inhibitor of poly ADP-ribose polymerase (nicotinamide), and angiotensin-converting enzyme inhibitor (trandolapril). The development of modern drugs to treat DN is a real challenge and needs intensive long-term comparative trials.
登录
查看更多内容
影响因子：
16.2
作者：
Freeman R;Durso-Decruz E;Emir B
通讯作者：
Emir B
影响因子：
7.4
作者：
Dalmolin, Gerusa Duarte;Silva, Cassia Regina;Ferreira, Juliano
通讯作者：
Ferreira, Juliano
影响因子：
3.8
作者：
Bril, Vera
通讯作者：
Bril, Vera
影响因子：
--
作者：
Barbano, RL;Herrmann, DN;Dworkin, RH
通讯作者：
Dworkin, RH
影响因子：
7.4
作者：
Goldstein, DJ;Lu, YL;Iyengar, S
通讯作者：
Iyengar, S